Evaluating the Value of Amphiregulin, Phosphatase and Tensin Homologue (PTEN) and P21 Expression for Anti-EGFR Treatment in Metastatic Colorectal Carcinoma

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2021 Apr 28

PMID 33906293

Authors

Ahmed Ali Obaya

Amrallah A Mohammed

Hanaa Rashied

Adel Mahmoud Morsy

Gamal Osman

Ahmed S Allam

Ahmed M Elsayed

Ola A Harb

Walid S H Elsayed

Affiliations

Soon will be listed here.

Abstract

Background: Despite the significant progress in target therapy for the treatment of metastatic colorectal carcinoma (mCRC), the overall survival isn't satisfactory.

Methods: We assessed the expression of Amphiregulin, PTEN, and P21 in sections from 23 paraffin blocks prepared from 23 patients with left-sided mCRC using immunohistochemistry (IHC). The relationship between their level of expressions, clinicopathological parameters, response to anti-EGFR, and prognosis were analyzed.

Results: High Amphiregulin, PTEN and low P21 expression levels were associated with low tumor grade (p= 0.038 and 0.025 respectively), better response to anti-EGFR treatment (p <0.001), and favorable outcome {progression-free survival (PFS) and overall survival (OS)} (p <0.05). There was a direct relation between Amphiregulin and PTEN expressions (phi coefficient=+0.840), while there was an inverse relation between P21expression and both Amphiregulin (phi coefficient= -0.840) and PTEN expressions (phi coefficient = -1.000), which was statistically significant (P <0.001).

Conclusion: High Amphiregulin and PTEN expression levels and low P21 expression levels were associated with better response to anti-EGFR therapy and improved survival outcome. They might be considered predictive markers of response to anti-EGFR therapy in mCRC.<br /> <br />.

References

Shao Y, Shen Y, Chen T, Xu F, Chen X, Zheng S . The functions and clinical applications of tumor-derived exosomes. Oncotarget. 2016; 7(37):60736-60751. PMC: 5312416. DOI: 10.18632/oncotarget.11177. View

Okada Y, Miyamoto H, Goji T, Takayama T . Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer. Digestion. 2014; 89(1):18-23. DOI: 10.1159/000356202. View

Khelwatty S, Essapen S, Bagwan I, Green M, Seddon A, Modjtahedi H . The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Oncotarget. 2016; 8(5):7666-7677. PMC: 5352351. DOI: 10.18632/oncotarget.13835. View

Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A . PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer. 2012; 11(2):143-50. PMC: 3350566. DOI: 10.1016/j.clcc.2011.12.001. View

Spano J, Milano G, Vignot S, Khayat D . Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit Rev Oncol Hematol. 2008; 66(1):21-30. DOI: 10.1016/j.critrevonc.2007.11.005. View

Ma L, de Roquancourt A, Bertheau P, Chevret S, Millot G, Sastre-Garau X . Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions. J Pathol. 2001; 194(4):413-9. DOI: 10.1002/path.902. View

Ueno H, Kajiwara Y, Shimazaki H, Shinto E, Hashiguchi Y, Nakanishi K . New criteria for histologic grading of colorectal cancer. Am J Surg Pathol. 2012; 36(2):193-201. DOI: 10.1097/PAS.0b013e318235edee. View

Li X, Miao S, Wang G, Yang L, Shu Y, Yin Y . Amphiregulin and epiregulin expression in colorectal carcinoma and the correlation with clinicopathological characteristics. Onkologie. 2010; 33(7):353-8. DOI: 10.1159/000315380. View

Abbas T, Dutta A . p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009; 9(6):400-14. PMC: 2722839. DOI: 10.1038/nrc2657. View

10.

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J . Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011; 3(99):99ra86. PMC: 3268675. DOI: 10.1126/scitranslmed.3002442. View

11.

Kim E, Davidson L, Zoh R, Hensel M, Salinas M, Patil B . Rapidly cycling Lgr5 stem cells are exquisitely sensitive to extrinsic dietary factors that modulate colon cancer risk. Cell Death Dis. 2016; 7(11):e2460. PMC: 5260883. DOI: 10.1038/cddis.2016.269. View

12.

Zarkavelis G, Boussios S, Papadaki A, Katsanos K, Christodoulou D, Pentheroudakis G . Current and future biomarkers in colorectal cancer. Ann Gastroenterol. 2017; 30(6):613-621. PMC: 5670280. DOI: 10.20524/aog.2017.0191. View

13.

Mao C, Liao R, Chen Q . Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer. Br J Cancer. 2010; 102(5):940. PMC: 2833261. DOI: 10.1038/sj.bjc.6605575. View

14.

Chen Y, Shi Y, Lin J, Ye Y, Wang X, Chen G . Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. Medicine (Baltimore). 2015; 94(40):e1698. PMC: 4616741. DOI: 10.1097/MD.0000000000001698. View

15.

Negri F, Bozzetti C, Lagrasta C, Crafa P, Bonasoni M, Camisa R . PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer. 2009; 102(1):162-4. PMC: 2813733. DOI: 10.1038/sj.bjc.6605471. View

16.

Kastan M, Bartek J . Cell-cycle checkpoints and cancer. Nature. 2004; 432(7015):316-23. DOI: 10.1038/nature03097. View

17.

Sunakawa Y, Yang D, Moran M, Astrow S, Tsuji A, Stephens C . Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer. Cancer Biol Ther. 2016; 17(7):751-9. PMC: 4970538. DOI: 10.1080/15384047.2016.1178426. View

18.

Yarden Y, Sliwkowski M . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127-37. DOI: 10.1038/35052073. View

19.

Ross J, Torres-Mora J, Wagle N, Jennings T, Jones D . Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol. 2010; 134(3):478-90. DOI: 10.1309/AJCP2Y8KTDPOAORH. View

20.

Mellinghoff I, Cloughesy T, Mischel P . PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2007; 13(2 Pt 1):378-81. DOI: 10.1158/1078-0432.CCR-06-1992. View